This is a working overview of actin-binding fragment, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-04. Anything still debated is marked as such rather than presented as settled.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
Experiments manipulating the oxygen content, carbon dioxide content, and pH of bowfin extradural fluid did not affect breathing rate, heart rate, or blood pressure, pointing to a lack of central chemoreceptor regulation. Instead, bowfin respiratory patterns respond to water oxygen content and water temperature, as water temperatures play a role in oxygen content. In the laboratory, bowfin showed an increase in breathing rate when the temperatures were raised above 10 °C. Bowfin also showed an increase in breathing rate when exposed to lower oxygen levels in the water. Herpetologist W. T. Neill reported in 1950 that he unearthed a bowfin aestivating (in a dormant state) in a chamber 4 inches (10 cm) below the ground surface, 8 inches (20 cm) in diameter, 0.25 miles (0.4 km) from a river. Flood levels, of note, had previously reached the area and receded. Not unusually, riverine species like bowfin move into backwaters with flood currents and become trapped when water levels recede. While aestivation is anecdotally documented by multiple researchers, laboratory experiments have suggested, instead, that bowfin are physiologically incapable of surviving more than 3 to 5 days of air exposure, but no field manipulation has been performed. Regardless of the lack of evidence confirming the bowfin's ability to aestivate, bowfin can survive prolonged conditions of exposure to air because they have the ability to breathe air. Their gill filaments and lamellae are rigid in structure, which helps prevent the lamellae from collapsing and aids gas exchange even during air exposure.
The main Imperial Russian Army was commanded by Field Marshal Michael Andreas Barclay de Tolly, who recognized that Napoleon's immediate goal was a decisive battle to crush the main Russian force in the west. In response, the Russian army used scorched-earth tactics as it withdrew east, and harried the Grande Armée with light Cossack cavalry. The Grande Armée did not adjust its operational methods in response. Provisioning such an enormous army with adequate food and fresh water had proven difficult since the very start of the campaign, exacerbated by the sparse terrain of western Russia; diseases such as typhus and dysentery rapidly became rampant among the rank and file. These factors led to most of the losses of the main column of the Grande Armée, which in one case amounted to 95,000 men, including deserters, in a week. The main Russian army retreated for almost three months. This constant retreat led to the increasing unpopularity of Barclay de Tolly (who was a Baltic German and already mistrusted by the Russian elite) and a respected Russian veteran, Prince Mikhail Kutuzov, was made the new Commander-in-Chief by Tsar Alexander. Finally, the two armies engaged in the Battle of Borodino on 7 September, in the vicinity of Moscow. The battle was the largest and bloodiest single-day action of the Napoleonic Wars, involving more than 250,000 men and resulting in at least 70,000 casualties. The battle was indecisive; the French captured the main positions on the battlefield but failed to destroy the Russian army.
Some mushrooms are used in folk medicine. In a few countries, extracts, such as polysaccharide-K, schizophyllan, polysaccharide peptide, or lentinan, are government-registered adjuvant cancer therapies, but clinical evidence for efficacy and safety of these extracts in humans has not been confirmed. Although some mushroom species or their extracts may be consumed for therapeutic effects, some regulatory agencies, such as the US Food and Drug Administration, regard such use as a dietary supplement, which does not have government approval or common clinical use as a prescription drug.
Sources: en.wikipedia.org
==== Release ==== The decision to release Olofsson came after a negotiation on conditional release in Belgium at the end of May 2018. On 30 July 2018, Olofsson landed at Landvetter Airport outside Gothenburg, Sweden as a free man.
Extracardiac biopsies of tissues of the kidney, liver, peripheral nerve, or abdominal fat can be used to confirm the presence of amyloid deposits. Amyloid deposits in biopsy samples are confirmed through the use of Congo red dye, which produces a green birefringence when viewed under polarized light. Sirius red staining or electron microscopy examination can also be done. The determination of the type of amyloid can be done by immunohisto-labeling techniques as well as immunofluorescence staining. For light-chain amyloidosis patients, bone marrow biopsies could be conducted to determine the baseline percentage of plasma cells and to rule out multiple myeloma.
Supermarkets make up for their low margins by a high volume of sales, and with sales of higher-margin items bought by the customers. Self-service with shopping carts (trolleys) or baskets reduces labor costs, and many supermarket chains are attempting further reduction by shifting to self-service check-outs.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.